Neurocrine Biosciences (NBIX) Consolidated Net Income (2010 - 2026)

Neurocrine Biosciences' Consolidated Net Income history runs 17 years deep, the most recent figure standing at $197.9 million for Q1 2026.

• Quarterly Consolidated Net Income rose 2405.06% year-over-year to $197.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $668.6 million (up 118.64% YoY) and the FY2025 annual result came in at $478.6 million, up 40.23% from the prior year.
• Consolidated Net Income was $197.9 million for Q1 2026 at Neurocrine Biosciences, up from $153.7 million in the prior quarter.
• Across five years, Consolidated Net Income topped out at $209.5 million in Q3 2025 and bottomed at -$76.6 million in Q1 2023.
• A 5-year average of $83.6 million and a median of $89.0 million in 2022 frame the typical range for Consolidated Net Income.
• Annual changes were most pronounced in 2023 — Consolidated Net Income slumped 651.08% — and 2026, when it soared 2405.06%.
• Neurocrine Biosciences' Consolidated Net Income stood at $89.0 million in 2022, then soared by 65.96% to $147.7 million in 2023, then plunged by 30.2% to $103.1 million in 2024, then jumped by 49.08% to $153.7 million in 2025, then advanced by 28.76% to $197.9 million in 2026.
• Business Quant data shows NBIX's Consolidated Net Income at $197.9 million in Q1 2026, $153.7 million in Q4 2025, and $209.5 million in Q3 2025.